{"id":"NCT00260429","sponsor":"Stony Brook University","briefTitle":"Collagenase in the Treatment of Dupuytrens Disease","officialTitle":"Double-blind, Randomized Placebo Controlled Study of the Relative Safety and Efficacy of Collagenase Therapy in the Treatment of Residual-type Dupuytren's Disease.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-06","primaryCompletion":"2005-08","completion":"2008-04","firstPosted":"2005-12-01","resultsPosted":"2010-12-09","lastUpdate":"2010-12-09"},"enrollment":38,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Dupuytren's Disease"],"interventions":[{"type":"BIOLOGICAL","name":"collagenase clostridium histolyticum","otherNames":["XIAFLEXÂ®","AA4500"]}],"arms":[{"label":"AA4500 0.58 mg","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to determine if collagenase will reduce the degree of contracture in the primary joint in subjects with Dupuytren's disease.\n\nThis study was designed to be part of the larger clinical program, for adult patients with Dupuytren's contracture with a palpable cord, where the data from 2 pivotal Placebo-Controlled studies (AUX-CC-857 and AUX-CC-859) and 7 non-pivotal studies were evaluated.","primaryOutcome":{"measure":"Primary Outcome Measure is Reduction of Flexion Contracture of the Primary Joint.","timeFrame":"30 days after the last injection","effectByArm":[{"arm":"AA4500","deltaMin":91.3,"sd":null},{"arm":"Placebo","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["12239666"],"seeAlso":["http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125338lbl.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":23},"commonTop":["Injection site pain","Edema peripheral","Ecchymosis","Blood blister","Lymphadenopathy"]}}